| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $0 | 0 | 0 |
Sells | $43,014,096 | 15 | 100 |
| Delaet Ingrid | Chief Regulatory Officer | 0 | $0 | 1 | $61,695 | $-61,695 |
| Lippoldt Darin | Chief Legal Officer | 0 | $0 | 1 | $698,615 | $-698,615 |
| BENEVICH ERIC | Chief Commercial Officer | 0 | $0 | 1 | $905,881 | $-905,881 |
| Norwalk Leslie V | director | 0 | $0 | 2 | $945,702 | $-945,702 |
| MORROW GEORGE J | director | 0 | $0 | 1 | $2.15M | $-2.15M |
| LYONS GARY A | director | 0 | $0 | 1 | $2.29M | $-2.29M |
| Gano Kyle | Chief Executive Officer | 0 | $0 | 2 | $4.87M | $-4.87M |
| RASTETTER WILLIAM H | director | 0 | $0 | 2 | $6.04M | $-6.04M |
| Onyia Jude | Chief Scientific Officer | 0 | $0 | 2 | $10.45M | $-10.45M |
| GORMAN KEVIN CHARLES | director | 0 | $0 | 2 | $14.6M | $-14.6M |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Neurocrine Biosciences, Inc. have bought $0 and sold $43.01M worth of Neurocrine Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Neurocrine Biosciences, Inc. have bought $0 and sold $51.85M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 59,000 shares for transaction amount of $351,345 was made by BVF PARTNERS L P/IL (10 percent owner) on 2011‑10‑12.
| 2026-01-16 | Sale | Gano Kyle | Chief Executive Officer | 36,400 0.0367% | $132.70 | $4.83M | -0.94% | |
| 2025-12-16 | Sale | Norwalk Leslie V | director | 1,190 0.0012% | $155.09 | $184,558 | -10.78% | |
| 2025-12-15 | Sale | Norwalk Leslie V | director | 5,000 0.005% | $152.23 | $761,144 | -13.84% | |
| 2025-12-08 | Sale | Lippoldt Darin | Chief Legal Officer | 4,376 0.0045% | $159.65 | $698,615 | -13.96% | |
| 2025-12-03 | Sale | LYONS GARY A | director | 15,000 0.0152% | $152.61 | $2.29M | -12.04% | |
| 2025-11-28 | Sale | BENEVICH ERIC | Chief Commercial Officer | 5,970 0.006% | $151.74 | $905,881 | -11.60% | |
| 2025-11-25 | Sale | MORROW GEORGE J | director | 15,000 0.0153% | $143.37 | $2.15M | -6.26% | |
| 2025-11-05 | Sale | RASTETTER WILLIAM H | director | 18,000 0.0192% | $151.82 | $2.73M | -11.51% | |
| 2025-11-04 | Sale | Gano Kyle | Chief Executive Officer | 300 0.0003% | $141.97 | $42,591 | -4.94% | |
| 2025-08-07 | Sale | GORMAN KEVIN CHARLES | director | 106,322 0.1079% | $126.41 | $13.44M | +9.83% | |
| 2025-07-10 | Sale | Delaet Ingrid | Chief Regulatory Officer | 457 0.0005% | $135.00 | $61,695 | +1.76% | |
| 2025-07-09 | Sale | Onyia Jude | Chief Scientific Officer | 59,819 0.0591% | $130.46 | $7.8M | +2.79% | |
| 2025-07-02 | Sale | Onyia Jude | Chief Scientific Officer | 20,362 0.0207% | $130.13 | $2.65M | +5.87% | |
| 2025-05-27 | Sale | GORMAN KEVIN CHARLES | director | 9,613 0.0095% | $120.38 | $1.16M | +10.42% | |
| 2025-05-05 | Sale | RASTETTER WILLIAM H | director | 30,000 0.0304% | $110.20 | $3.31M | +22.56% | |
| 2025-02-14 | Sale | ROBERTS EIRY | Chief Medical Officer | 500 0.0005% | $115.04 | $57,521 | +16.04% | |
| 2025-02-13 | Sale | GORMAN KEVIN CHARLES | director | 5,844 0.0057% | $116.69 | $681,914 | +14.20% | |
| 2025-02-13 | Sale | Gano Kyle | Chief Executive Officer | 2,558 0.0025% | $116.85 | $298,908 | +14.20% | |
| 2025-02-13 | Sale | BENEVICH ERIC | Chief Commercial Officer | 2,154 0.0021% | $116.73 | $251,428 | +14.20% | |
| 2025-02-13 | Sale | Lippoldt Darin | Chief Legal Officer | 2,184 0.0021% | $116.75 | $254,992 | +14.20% |
| GORMAN KEVIN CHARLES | director | 514596 0.5127% | $67.74M | 0 | 64 | |
| Gano Kyle | Chief Executive Officer | 140407 0.1399% | $18.48M | 0 | 55 | |
| LYONS GARY A | director | 120482 0.12% | $15.86M | 0 | 48 | |
| BENEVICH ERIC | Chief Commercial Officer | 44893 0.0447% | $5.91M | 0 | 43 | |
| Lippoldt Darin | Chief Legal Officer | 43405 0.0432% | $5.71M | 0 | 59 | |
| RASTETTER WILLIAM H | director | 40360 0.0402% | $5.31M | 0 | 10 | |
| Onyia Jude | Chief Scientific Officer | 18289 0.0182% | $2.41M | 0 | 12 | |
| MORROW GEORGE J | director | 7068 0.007% | $930,431.52 | 0 | 2 | |
| Norwalk Leslie V | director | 6239 0.0062% | $821,301.96 | 0 | 4 | |
| Delaet Ingrid | Chief Regulatory Officer | 4730 0.0047% | $622,657.20 | 0 | 24 | |
| BVF PARTNERS L P/IL | 10 percent owner | 3527700 3.5149% | $464.39M | 36 | 10 | <0.0001% |
| VALE WYLIE W | director | 231372 0.2305% | $30.46M | 0 | 18 | |
| Bozigian Haig P. | Chief Development Officer | 154934 0.1544% | $20.4M | 0 | 65 | |
| Coughlin Timothy P | Chief Financial Officer | 137961 0.1375% | $18.16M | 0 | 32 | |
| HAWRAN PAUL W | Executive VP and CFO | 132000 0.1315% | $17.38M | 0 | 3 | |
| VALEUR JENSEN MARGARET E | EVP and General Counsel | 118256 0.1178% | $15.57M | 0 | 7 | |
| Grigoriadis Dimitri E. | Chief Research Officer | 82273 0.082% | $10.83M | 0 | 71 | |
| CONLON PAUL J | Vice President Research (Biol) | 57335 0.0571% | $7.55M | 0 | 2 | |
| OBrien Christopher Flint | Former Chief Medical Officer | 52223 0.052% | $6.87M | 0 | 51 | |
| Nevinny Corinne H | director | 43283 0.0431% | $5.7M | 0 | 3 | |
| Lloyd-Smith Malcolm | Chief Integration Officer | 42337 0.0422% | $5.57M | 0 | 34 | |
| ROBERTS EIRY | Chief Medical Officer | 35640 0.0355% | $4.69M | 0 | 31 | |
| ABERNETHY MATT | Chief Financial Officer | 34775 0.0346% | $4.58M | 0 | 29 | |
| POPS RICHARD F | director | 31611 0.0315% | $4.16M | 0 | 12 | |
| Cooke Julie | Chief Human Resources Officer | 19544 0.0195% | $2.57M | 0 | 35 | |
| STEINMAN LAWRENCE | director | 15500 0.0154% | $2.04M | 0 | 2 | |
| SHERWIN STEPHEN A | director | 10673 0.0106% | $1.4M | 0 | 7 | |
| RANIERI RICHARD J | Sr. VP, Human Resources | 9667 0.0096% | $1.27M | 0 | 1 | |
| SAUNDERS JOHN | Vice President Research (Chem) | 2916 0.0029% | $383,862.24 | 0 | 3 | |
| Boyer David W. | Chief Corp. Affairs Officer | 2854 0.0028% | $375,700.56 | 0 | 20 | |
| MITCHELL W THOMAS | director | 1000 0.001% | $131,640.00 | 2 | 7 | +29.05% |
| Sharp Shalini | director | 994 0.001% | $130,850.16 | 0 | 1 |
$910,099,463 | 123 | 11.52% | $2B | |
$25,613,591 | 65 | -3.30% | $11.66B | |
$14,599,168 | 59 | 12.79% | $1.8B | |
$102,709,455 | 46 | 30.55% | $1.02B | |
$11,542,910 | 40 | 56.19% | $1.39B | |
$73,312,053 | 38 | -4.38% | $1.46B | |
Neurocrine Biosciences, Inc. (NBIX) | $21,020,549 | 38 | -2.84% | $13.21B |
$12,998,723 | 30 | 3.46% | $4.03B | |
$6,506,230 | 27 | -16.20% | $980.78M | |
$25,034,841 | 20 | 9.38% | $587.01M | |
$78,335,024 | 20 | 4.76% | $52.88B | |
$83,406,412 | 19 | 21.96% | $2.97B | |
$2,233,486 | 16 | -3.31% | $15.67B | |
$1,843,996 | 10 | 22.92% | $959.02M | |
$26,633,903 | 9 | 42.23% | $1.12B | |
$1,718,514 | 9 | 38.13% | $783.21M | |
$141,200 | 8 | 41.74% | $5.3B | |
$725,133 | 7 | 30.62% | $2.4B | |
$32,954,224 | 5 | -0.22% | $36.05B |
| Increased Positions | 427 | +67.67% | 11M | +11.22% |
| Decreased Positions | 268 | -42.47% | 9M | -8.89% |
| New Positions | 140 | New | 2M | New |
| Sold Out Positions | 42 | Sold Out | 1M | Sold Out |
| Total Postitions | 790 | +25.2% | 100M | +2.33% |
| Blackrock, Inc. | $1.79M | 12.71% | 12.71M | -248,535 | -1.92% | 2025-09-30 |
| Vanguard Group Inc | $1.36M | 9.71% | 9.71M | -100,507 | -1.02% | 2025-09-30 |
| Dodge & Cox | $781,260.00 | 5.56% | 5.56M | -10,196 | -0.18% | 2025-09-30 |
| Jpmorgan Chase & Co | $665,059.00 | 4.73% | 4.73M | +468,405 | +10.99% | 2025-09-30 |
| State Street Corp | $611,115.00 | 4.35% | 4.35M | -121,787 | -2.73% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $403,062.00 | 2.87% | 2.87M | -219,726 | -7.12% | 2025-09-30 |
| Aqr Capital Management Llc | $389,975.00 | 2.77% | 2.77M | +1M | +83.68% | 2025-09-30 |
| Renaissance Technologies Llc | $340,013.00 | 2.42% | 2.42M | +51,900 | +2.19% | 2025-09-30 |
| Geode Capital Management, Llc | $284,690.00 | 2.03% | 2.02M | +65,560 | +3.35% | 2025-09-30 |
| Morgan Stanley | $256,867.00 | 1.83% | 1.83M | +7,192 | +0.4% | 2025-09-30 |